Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Earns Outperform Rating from Analysts at Evercore

Evercore assumed coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a report issued on Wednesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $46.00 target price on the stock.

Several other research analysts have also recently weighed in on the stock. Wall Street Zen raised shares of Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Leerink Partners initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, January 7th. They set an “outperform” rating and a $46.00 price objective for the company. Guggenheim reaffirmed a “buy” rating and set a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Zacks Research upgraded shares of Damora Therapeutics, Inc. Common Stock to a “hold” rating in a report on Friday, January 9th. Finally, Lifesci Capital raised shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock currently has an average rating of “Moderate Buy” and an average price target of $44.25.

Damora Therapeutics, Inc. Common Stock Stock Performance

NASDAQ DMRA opened at $25.50 on Wednesday. The stock’s fifty day moving average is $27.02 and its two-hundred day moving average is $19.65. The firm has a market capitalization of $1.54 billion, a P/E ratio of -2.11 and a beta of 1.42. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $2.01 and a fifty-two week high of $38.33.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Hedge funds and other institutional investors have recently modified their holdings of the business. Ikarian Capital LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth about $6,574,000. Janus Henderson Group PLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at about $40,000. Boothbay Fund Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $2,204,000. Jain Global LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $2,774,000. Finally, Remedium Capital Partners LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $2,772,000. 14.20% of the stock is owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.